HPG1860

Hepagene (Shanghai) Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	HPG1860
Sponsor	Hepagene (Shanghai) Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2a Study of HPG1860 in Subjects With NASH (PHASE2)
Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HPG1860 CI brief — competitive landscape report
HPG1860 updates RSS · CI watch RSS
Hepagene (Shanghai) Co., Ltd. portfolio CI